|
Pacific Biosciences de California, Inc. (PACB) Valoración de DCF
US | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Pacific Biosciences of California, Inc. (PACB) Bundle
¡Ahorre tiempo y mejore la precisión con nuestra calculadora DCF (PACB)! Equipados con datos reales de Pacific Biosciences de California, Inc. y suposiciones personalizables, esta herramienta le permite pronosticar, analizar y valor (PACB) al igual que un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.9 | 78.9 | 130.5 | 128.3 | 200.5 | 254.1 | 321.9 | 407.9 | 516.8 | 654.9 |
| Revenue Growth, % | 0 | -13.2 | 65.43 | -1.69 | 56.29 | 26.71 | 26.71 | 26.71 | 26.71 | 26.71 |
| EBITDA | -71.6 | 39.0 | -250.8 | -282.2 | -277.3 | -167.4 | -212.0 | -268.7 | -340.4 | -431.3 |
| EBITDA, % | -78.75 | 49.4 | -192.13 | -219.98 | -138.28 | -65.87 | -65.87 | -65.87 | -65.87 | -65.87 |
| Depreciation | 9.9 | 9.3 | 11.6 | 17.3 | 26.5 | 29.6 | 37.6 | 47.6 | 60.3 | 76.4 |
| Depreciation, % | 10.94 | 11.79 | 8.88 | 13.5 | 13.23 | 11.67 | 11.67 | 11.67 | 11.67 | 11.67 |
| EBIT | -81.5 | 29.7 | -262.3 | -299.6 | -303.8 | -178.9 | -226.7 | -287.2 | -363.9 | -461.1 |
| EBIT, % | -89.69 | 37.61 | -201.01 | -233.48 | -151.51 | -70.42 | -70.42 | -70.42 | -70.42 | -70.42 |
| Total Cash | 49.1 | 318.8 | 1,044.4 | 772.3 | 631.4 | 230.7 | 292.3 | 370.4 | 469.3 | 594.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 15.3 | 16.8 | 24.2 | 18.8 | 36.6 | 45.5 | 57.7 | 73.1 | 92.6 | 117.4 |
| Account Receivables, % | 16.8 | 21.34 | 18.57 | 14.64 | 18.26 | 17.92 | 17.92 | 17.92 | 17.92 | 17.92 |
| Inventories | 13.3 | 14.2 | 24.6 | 50.4 | 56.7 | 60.5 | 76.7 | 97.1 | 123.1 | 155.9 |
| Inventories, % | 14.65 | 18.04 | 18.85 | 39.27 | 28.26 | 23.81 | 23.81 | 23.81 | 23.81 | 23.81 |
| Accounts Payable | 8.4 | 3.6 | 11.0 | 12.0 | 15.1 | 19.8 | 25.1 | 31.9 | 40.4 | 51.2 |
| Accounts Payable, % | 9.21 | 4.54 | 8.43 | 9.37 | 7.51 | 7.81 | 7.81 | 7.81 | 7.81 | 7.81 |
| Capital Expenditure | -2.8 | -1.0 | -5.9 | -16.9 | -8.8 | -13.5 | -17.1 | -21.7 | -27.5 | -34.8 |
| Capital Expenditure, % | -3.12 | -1.32 | -4.54 | -13.19 | -4.41 | -5.32 | -5.32 | -5.32 | -5.32 | -5.32 |
| Tax Rate, % | 3.59 | 3.59 | 3.59 | 3.59 | 3.59 | 3.59 | 3.59 | 3.59 | 3.59 | 3.59 |
| EBITAT | -75.4 | 29.7 | -173.0 | -283.0 | -292.9 | -160.8 | -203.7 | -258.1 | -327.0 | -414.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -88.5 | 30.7 | -177.7 | -302.0 | -296.3 | -152.6 | -206.3 | -261.4 | -331.2 | -419.6 |
| WACC, % | 7.41 | 7.63 | 6.63 | 7.47 | 7.53 | 7.33 | 7.33 | 7.33 | 7.33 | 7.33 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,076.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -428 | |||||||||
| Terminal Value | -8,026 | |||||||||
| Present Terminal Value | -5,634 | |||||||||
| Enterprise Value | -6,711 | |||||||||
| Net Debt | 754 | |||||||||
| Equity Value | -7,465 | |||||||||
| Diluted Shares Outstanding, MM | 254 | |||||||||
| Equity Value Per Share | -29.43 |
What You Will Get
- Real PACB Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures to fit your analysis.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess the future performance of Pacific Biosciences.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive PACB Data: Pre-filled with Pacific Biosciences' historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth rates, profit margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Instant updates to Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Testing: Develop multiple forecasting scenarios to explore various valuation results.
- User-Friendly Interface: Intuitive design that caters to both professionals and novices.
How It Works
- Download the Template: Gain immediate access to the Excel-based PACB DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically recalculates the intrinsic value of Pacific Biosciences.
- Test Scenarios: Experiment with different assumptions to assess potential valuation variations.
- Analyze and Decide: Leverage the results to inform your investment or financial strategy.
Why Choose This Calculator for Pacific Biosciences (PACB)?
- Accuracy: Utilizes real Pacific Biosciences financial data for precise calculations.
- Flexibility: Allows users to easily adjust and test various input parameters.
- Time-Saving: Eliminate the need to construct a DCF model from the ground up.
- Professional-Grade: Crafted with the precision and usability expected by financial executives.
- User-Friendly: Designed for ease of use, suitable for users with varying levels of financial expertise.
Who Should Use This Product?
- Investors: Assess Pacific Biosciences’ valuation before making stock transactions.
- CFOs and Financial Analysts: Optimize valuation methodologies and evaluate forecasts.
- Startup Founders: Understand the valuation processes of leading biotech firms like Pacific Biosciences.
- Consultants: Provide expert valuation analyses and reports for clients in the biotech sector.
- Students and Educators: Utilize current data to learn and teach valuation strategies in a real-world context.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Pacific Biosciences of California, Inc. (PACB).
- Real-World Data: Pacific Biosciences’ historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results specific to Pacific Biosciences of California, Inc. (PACB).